Advancements in CRISPR/Cas Technologies for Sensitive Cancer Detection: Mechanisms, Platforms, and Clinical Translation Roadmap
Diagnostics · 11.08.2026 · 16 (16) · 2531
DOI: 10.3390/diagnostics16162531 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 11.08.2026. Verfasst von Rokeya Akter und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Wonju College of Medicine, Yonsei University, Wonju 26426, Republic of Korea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 180 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Early cancer detection is critical for improving patient outcomes, yet current diagnostic approaches often fail to identify malignancies when tumor-specific biomarkers are relatively scarce. Emerging CRISPR/Cas-based technologies have revolutionized the ultra-sensitive detection of cancer biomarkers in liquid biopsies, overcoming the inherent limitations of traditional diagnostic approaches such as tissue biopsies and imaging, which frequently fail to detect early-stage malignancies with sufficient sensitivity. This review explores recent advances in CRISPR/Cas diagnostics (CRISPR/Cas-Dx) that employ programmable CRISPR effectors, including Cas9, Cas12, Cas13, and Cas14. In particular, the collateral (trans-) cleavage activities of Cas12, Cas13, and Cas14 enable signal amplification for highly sensitive detection of circulating tumor DNA, microRNAs, exosomes, and other multi-omics biomarkers, often without the need for extensive nucleic acid amplification. Representative CRISPR/Cas-Dx platforms include amplification-coupled assays, amplification-free frameworks, biosensing and multiplexing capabilities, and new digital or droplet-based configurations that include artificial intelligence to improve analytical precision. These technologies demonstrate single-molecule resolution and adaptability for point-of-care testing in malignancies such as non-small cell lung, colorectal, and breast carcinoma. Finally, we outline a clinical translation roadmap encompassing manufacturability, regulatory and standardization requirements, and real-world implementation challenges. This perspective offers a blueprint for CRISPR-powered, ultra-sensitive liquid biopsy diagnostics that can enable population-scale early cancer screening and truly preventive oncology by bridging molecular insights, engineering innovation, and clinical imperatives.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Wonju College of Medicine, Yonsei University, Wonju 26426, Republic of Korea.
- Department of Laboratory Medicine, Kangwon National University School of Medicine, Chuncheon 24341, Republic of Korea.
- Research Institute of Metabolism and Inflammation, Wonju College of Medicine, Yonsei University, Wonju 26426, Republic of Korea.
ORCID-Profile: Sook Won Ryu, Jong-Han Lee
Zitieren
APA
Akter, R., Ryu, S. W., & Lee, J. H. (2026). Advancements in CRISPR/Cas Technologies for Sensitive Cancer Detection: Mechanisms, Platforms, and Clinical Translation Roadmap. Diagnostics, 16(16), 2531. https://doi.org/10.3390/diagnostics16162531
Vancouver
Akter R, Ryu SW, Lee JH. Advancements in CRISPR/Cas Technologies for Sensitive Cancer Detection: Mechanisms, Platforms, and Clinical Translation Roadmap. Diagnostics. 2026;16(16):2531. doi:10.3390/diagnostics16162531
BibTeX
@article{Akter2026,
author = {Akter, Rokeya and Ryu, Sook Won and Lee, Jong-Han},
title = {Advancements in CRISPR/Cas Technologies for Sensitive Cancer Detection: Mechanisms, Platforms, and Clinical Translation Roadmap},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {16},
pages = {2531},
doi = {10.3390/diagnostics16162531}
}
EUVIMED